152 results
Page 2 of 8
8-K
EX-99.1
evuz7
3 Oct 23
Regeneron and Intellia Announce Expanded Research Collaboration
7:19am
8-K
EX-99.1
i11jv 84p
3 Aug 23
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:45am
8-K
EX-99.1
trrkn3 dcqgd
12 Jun 23
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of
7:00am
8-K
nvs2n4r5gwpse
12 Jun 23
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of
7:00am
DEFA14A
nwrckdvkc17oe5yp
5 Jun 23
Additional proxy soliciting materials
5:16pm
8-K
EX-99.1
vcsiobo3p
5 Jun 23
Departure of Directors or Certain Officers
4:52pm
8-K
EX-99.1
o2mbaf b6hhuyo9058c
4 May 23
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:41am
8-K
EX-99.1
kwz65
17 Apr 23
Intellia Therapeutics Names Bill Chase to its Board of Directors
4:59pm
8-K
ppv6rds19reb
1 Dec 22
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-1.1
m1upi4nk2e4mipz36
1 Dec 22
Entry into a Material Definitive Agreement
5:22pm
424B5
lpbzs053enp6yriyiaf
1 Dec 22
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.1
dchqhr vq
14 Nov 22
Intellia Therapeutics Presents New Interim Data
7:30am
8-K
5jlzp2t8uya
14 Nov 22
Intellia Therapeutics Presents New Interim Data
7:30am
8-K
ku4y5eugsfk2
7 Nov 22
Regulation FD Disclosure
4:42pm
8-K
EX-99.1
xhyqvewe9tk w1eb
7 Nov 22
Regulation FD Disclosure
4:42pm
8-K
EX-99.1
eyi8k5hr0h xz
3 Nov 22
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
7:40am